• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国 2 型糖尿病合并或不合并心血管疾病患者心血管风险因素的控制。

Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease.

机构信息

Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, California; Department of Population Health Sciences, University of California, Irvine, California.

Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, California; Department of Population Health Sciences, University of California, Irvine, California.

出版信息

Am J Cardiol. 2019 Aug 15;124(4):522-527. doi: 10.1016/j.amjcard.2019.05.035. Epub 2019 May 28.

DOI:10.1016/j.amjcard.2019.05.035
PMID:31239072
Abstract

Cardiovascular disease (CVD) remains leading cause of death among adults with type 2 diabetes (T2DM). There is a lack of recent national data on attainment of single and multiple CVD risk factor targets among adults with T2DM with and without CVD. We identified 1179 T2DM adults (projected to 19.7 million in the US population) aged ≥18 years from the US National Health and Nutrition Examination Survey (NHANES) 2013-2016 and examined those at target for hemoglobin A1c (HbA1c <7.0%, <8.0% if CVD), blood pressure (BP <130/80 mm Hg), low-density lipoprotein cholesterol (LDL-C <100 mg/dL non-CVD and LDL-C <70 mg/dL CVD), nonsmoking status, and body mass index (BMI <30 kg/mand BMI <25 kg/m) individually and as a composite in those with versus without prior CVD. Overall, around half of T2DM adults were at target control of HbA1c (55.8%), BP (51.3%), LDL-C (49.3%), with more being nonsmokers (84.3%). The proportion at target for these factors was slightly higher among those with CVD except for LDL-C. BMI was least frequently at target control (9.1% for BMI <25 kg/m) compared to other risk factors. Moreover, only 17.3% of T2DM patients reached composite target control of HbA1c, BP and LDL-C, with 16.0% reaching target control when nonsmoking status was included and <10% if we included BMI targets. The proportion of patients at composite control was lower in those with versus without with prior CVD. Less than one-fifth adults with T2DM are at composite CVD risk factor control for HbA1c, BP, LDL-C, and nonsmoking status.

摘要

心血管疾病 (CVD) 仍然是 2 型糖尿病 (T2DM) 患者的主要死亡原因。目前缺乏关于 T2DM 患者(无论是否患有 CVD)在单一和多种 CVD 风险因素目标方面的最新全国性数据。我们从美国国家健康和营养调查 (NHANES) 2013-2016 年的数据中确定了 1179 名年龄≥18 岁的 T2DM 成年人(预计在美国人口中为 1970 万),并检查了那些达到血红蛋白 A1c(HbA1c<7.0%,CVD 时<8.0%)、血压(BP<130/80mmHg)、低密度脂蛋白胆固醇(LDL-C<100mg/dL 非 CVD 和 LDL-C<70mg/dL CVD)、非吸烟状态和身体质量指数(BMI<30kg/m 和 BMI<25kg/m)的目标值的患者,分别在有或无既往 CVD 的患者中作为复合因素。总体而言,约一半的 T2DM 患者的 HbA1c(55.8%)、BP(51.3%)、LDL-C(49.3%)控制达标,更多的是不吸烟(84.3%)。除 LDL-C 外,有 CVD 的患者这些因素的达标比例略高。与其他危险因素相比,BMI 达标控制的比例最低(BMI<25kg/m 的比例为 9.1%)。此外,只有 17.3%的 T2DM 患者达到 HbA1c、BP 和 LDL-C 的综合目标控制,当包括非吸烟状态时,16.0%达到目标控制,当包括 BMI 目标时,<10%。与没有 CVD 的患者相比,有 CVD 的患者达到综合控制的比例较低。不到五分之一的 T2DM 患者达到 HbA1c、BP、LDL-C 和非吸烟状态的综合 CVD 危险因素控制。

相似文献

1
Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease.美国 2 型糖尿病合并或不合并心血管疾病患者心血管风险因素的控制。
Am J Cardiol. 2019 Aug 15;124(4):522-527. doi: 10.1016/j.amjcard.2019.05.035. Epub 2019 May 28.
2
Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status.2009 年至 2010 年美国成年 2 型糖尿病患者心血管风险因素控制趋势:按现患心血管疾病状况的比较。
Diab Vasc Dis Res. 2013 Nov;10(6):505-13. doi: 10.1177/1479164113496828. Epub 2013 Aug 22.
3
Depressive symptoms, serious psychological distress, diabetes distress and cardiovascular risk factor control in patients with type 2 diabetes.2型糖尿病患者的抑郁症状、严重心理困扰、糖尿病困扰及心血管危险因素控制
J Diabetes Complications. 2016 Mar;30(2):312-7. doi: 10.1016/j.jdiacomp.2015.11.010. Epub 2015 Nov 14.
4
Gender differences in composite control of cardiovascular risk factors among patients with type 2 diabetes.2型糖尿病患者心血管危险因素综合控制中的性别差异。
Diabetes Technol Ther. 2014 Jul;16(7):421-7. doi: 10.1089/dia.2013.0329. Epub 2014 Apr 15.
5
HEMOGLOBIN A1C, BLOOD PRESSURE, AND LDL-CHOLESTEROL CONTROL AMONG HISPANIC/LATINO ADULTS WITH DIABETES: RESULTS FROM THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL).西班牙裔/拉丁裔糖尿病成年患者的糖化血红蛋白、血压及低密度脂蛋白胆固醇控制情况:来自西班牙裔社区健康研究/拉丁裔研究(HCHS/SOL)的结果
Endocr Pract. 2017 Oct;23(10):1232-1253. doi: 10.4158/EP171765.OR. Epub 2017 Aug 17.
6
LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007-2016.LEADER 试验入选标准和美国糖尿病成年患者的可预防心血管事件:2007-2016 年全国健康和营养调查。
Cardiovasc Drugs Ther. 2020 Dec;34(6):737-743. doi: 10.1007/s10557-020-07032-7. Epub 2020 Jul 3.
7
Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study.糖尿病中的心血管危险因素目标与心血管疾病事件风险:社区动脉粥样硬化风险研究、多民族动脉粥样硬化研究及杰克逊心脏研究的汇总项目
Diabetes Care. 2016 May;39(5):668-76. doi: 10.2337/dc15-2439. Epub 2016 Mar 29.
8
The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.接受降脂药物治疗的 2 型糖尿病患者血脂异常的管理:CEPHEUS 研究结果的亚分析。
Curr Vasc Pharmacol. 2018;16(4):368-375. doi: 10.2174/1570161115666170705153815.
9
Type 1 diabetes management: Room for improvement.1 型糖尿病管理:仍有改进空间。
J Diabetes. 2023 Mar;15(3):255-263. doi: 10.1111/1753-0407.13368. Epub 2023 Feb 17.
10
Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.美国心脏病学会/美国心脏协会他汀类药物适宜性分组、他汀类药物使用情况以及美国成年人低密度脂蛋白胆固醇控制的流行率,使用的是 2011-2012 年全国健康和营养调查。
J Clin Lipidol. 2016 Sep-Oct;10(5):1109-18. doi: 10.1016/j.jacl.2016.06.011. Epub 2016 Jun 29.

引用本文的文献

1
Composite cardiovascular risk factor control in US adults with diabetes and relation to social determinants of health: The research program.美国糖尿病成年人的复合心血管危险因素控制及其与健康社会决定因素的关系:研究项目
Am J Prev Cardiol. 2025 Jan 30;21:100939. doi: 10.1016/j.ajpc.2025.100939. eCollection 2025 Mar.
2
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.《2025年心脏病和中风统计数据:美国心脏协会关于美国和全球数据的报告》
Circulation. 2025 Feb 25;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303. Epub 2025 Jan 27.
3
What Primary Care Clinicians Need to Know About Once-Weekly Insulins.
基层医疗临床医生需要了解的关于每周一次胰岛素的知识。
Fed Pract. 2024 Nov;41(Suppl 6):S47-S52. doi: 10.12788/fp.0536. Epub 2024 Nov 20.
4
Lipids as the link between central obesity and diabetes: perspectives from mediation analysis.脂质作为中心性肥胖与糖尿病之间的联系:中介分析的观点。
BMC Endocr Disord. 2024 Oct 28;24(1):229. doi: 10.1186/s12902-024-01764-5.
5
Polypills in the Management of Cardiovascular Risk-A Perspective.心血管风险管理中的复方制剂——一种观点
J Clin Med. 2024 Sep 16;13(18):5487. doi: 10.3390/jcm13185487.
6
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?2 型糖尿病未明残余风险:问题有多大?
Curr Cardiol Rep. 2024 Jun;26(6):623-633. doi: 10.1007/s11886-024-02055-0. Epub 2024 Apr 18.
7
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.2024 年心脏病与中风统计数据:美国心脏协会发布的美国和全球数据报告。
Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24.
8
Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial.一种评估2型糖尿病心血管疾病风险的新型检测方法的临床效用:一项随机对照试验。
Diabetol Metab Syndr. 2023 Jul 13;15(1):155. doi: 10.1186/s13098-023-01122-w.
9
Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.在高加索 2 型糖尿病患者中,芦格列净的疗效和安全性:一项 III 期、随机、安慰剂对照临床试验的结果。
BMJ Open Diabetes Res Care. 2023 Jun;11(3). doi: 10.1136/bmjdrc-2022-003290.
10
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention.糖尿病患者的心血管风险:流行病学、评估和预防。
Nat Rev Cardiol. 2023 Oct;20(10):685-695. doi: 10.1038/s41569-023-00877-z. Epub 2023 May 16.